U.S. prescription drug prices recorded their steepest annual decline in more than 60 years in July, falling 3.1 percent compared with July 2025, according to data released by the Bureau of Labor Statistics. The White House announced the drop as a major victory, with spokesman Kush Desai stating that “no president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump,” attributing the decline to the president’s pricing agreements with drug companies and TrumpRx, a direct-to-consumer platform launched earlier this year.
The 3.1 percent annual decline marks the largest drop since March 1963, a span of more than six decades. Over a six-month period ending in July, prescription drugs fell at a seasonally adjusted annual rate of 6.6 percent, the sharpest six-month decline on record, according to Renaissance Macro. While overall medical costs continued to rise, the prescription drug category stood out as one of the few bright spots in the consumer price index.
Multiple Forces Behind the Price Drop
Experts say the causes of the decline are more complex than the White House’s claims suggest. Richard Frank, a senior fellow at the Brookings Institution and professor emeritus of health economics at Harvard University, said the Inflation Reduction Act—a Biden-era policy that allows Medicare to negotiate prices for select high-cost drugs—is the more likely driver. “If I was a betting guy on what mattered most, it would be probably stuff around the Inflation Reduction Act,” Frank said.
The Inflation Reduction Act, enacted in 2022, required Medicare to begin negotiating prices for certain popular and costly prescription drugs. The first set of negotiated prices took effect at the beginning of 2026, covering 10 drugs and generating an estimated $6 billion in taxpayer savings. Stacie Dusetzina, a health policy professor at Vanderbilt University, noted that these 10 negotiated drugs are commonly used and “their prices would likely be reflected in the prescription drug index,” making them significant contributors to the overall decline.
GLP-1 weight-loss drugs also played a major role. TrumpRx offers GLP-1 drugs for as low as $150 for a starting dose, while a Medicare pilot program launched in July secured prices of $245 per month for Novo Nordisk and Eli Lilly products—Wegovy, Zepbound, and Foundayo. Monthly prices charged to insurance companies had previously topped $1,000. However, market competition from cheaper compounded versions and spotty insurance coverage for weight-loss uses have created downward pressure independent of government action.
A wave of blockbuster drugs losing patent protection in 2026 also contributed significantly. When brand-name drugs lose patent exclusivity, the Bureau of Labor Statistics swaps them for cheaper generics in its sample, recording the difference as a price reduction. Drugs including Merck’s Januvia and Janumet, and Pfizer’s Xeljanz have all lost or are losing exclusivity this year, and experts say these commonly filled medications likely pushed the overall index down.
Sources
- The Washington Post — reported the 3.1 percent year-over-year decline in July 2026, the steepest since March 1963, and provided expert analysis from Richard Frank and Stacie Dusetzina on contributing factors.
- The Fiscal Times — confirmed the 3.1 percent decline and the March 1963 baseline.
- Bureau of Labor Statistics — released the Consumer Price Index data showing the prescription drug price decline.
- Drug Discovery News — documented the wave of blockbuster drugs facing patent expiration in 2026.
